BELGRADE, Mont., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2023.
“Driven by strong organic growth of 18%, and contributions from our recent acquisitions, we achieved record third quarter revenue of $25 million, an increase of 73% year-over-year, and raised our 2023 revenue guidance range for the second consecutive quarter,” said Sean Browne, President and CEO of Xtant Medical. “I am extremely proud of our team’s efforts integrating Surgalign’s hardware and biologics business while growing our core business. These results and execution are a testament to their steadfast commitment and diligence. With the Surgalign integration progressing smoothly, we remain focused on optimizing our distribution network and further scaling operations. We look forward to building upon this momentum by bringing expanded solutions to patients in need and maximizing value to our shareholders.”
Third Quarter 2023 Financial Results
Third quarter 2023 revenue grew 73% to $25.0 million, compared to $14.5 million for the same quarter in 2022. Revenue includes organic growth of 18% plus a 55% increase from products added in the acquisition of the Coflex and CoFix lines and Surgalign hardware and biologics business. These revenue increases are attributed primarily to greater independent agent and private label sales, sales from the acquired Coflex and CoFix product lines, and sales from the acquisition of Surgalign.
Gross margin for the third quarter of 2023 was 61.3%, compared to 54.6% for the same period in 2022. The increase is primarily attributable to greater production efficiencies, decreased charges for excess and obsolete inventory, and product mix, partially offset by higher product costs.
Operating expenses for the third quarter of 2023 totaled $18.7 million, compared to $9.8 million for the third quarter of 2022. The increase was primarily due to additional independent agent sales commissions, higher employee compensation expenses, legal expenses, and amortization of intangible assets associated with the Coflex and CoFix product lines.
Third quarter 2023 net income totaled $9.2 million, or $0.07 per share, compared to the third quarter 2022 net loss of $2.4 million, or $0.03 per share.
Non-GAAP Adjusted EBITDA for the third quarter of 2023 was $0.5 million, compared to a Non-GAAP Adjusted EBITDA loss of $0.9 million for the prior-year period. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income taxes, and as further adjusted to add back in or exclude, as applicable, non-cash compensation, acquisition-related expenses, acquisition-related fair value adjustments, gain on bargain purchase, and litigation settlement reserve. A calculation and reconciliation of Adjusted EBITDA to net loss can be found in the attached financial tables.
2023 Financial Guidance
Xtant Medical raises its expectation for full year 2023 revenue to $88 million to $91 million, up from the Company’s prior guidance of $75 million to $77 million. The revised guidance range represents annual revenue growth of approximately 52% to 57% compared to full year 2022 revenue, and includes contributions from the Surgalign transaction.
Conference Call
Xtant Medical will host a webcast and conference call to discuss third quarter 2023 financial results on Thursday, November 9, 2023 at 9:00 AM ET. To access the webcast, Click Here. To access the conference call, dial 877-407-6184 within the U.S. or 201-389-0877 outside the U.S. A replay of the call will be available at www.xtantmedical.com, under “Investor Info.”
About Xtant Medical Holdings, Inc.
Xtant Medical’s mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Non-GAAP Financial Measures
To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA and organic revenue growth. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “intends,” ‘‘expects,’’ ‘‘anticipates,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential,” “going forward,” “guidance,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s financial guidance for 2023. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results and financial performance; its ability to increase or maintain revenue; risks associated with its recent acquisitions and the integration of those businesses; anticipated shortages of stem cells which will adversely affect future revenues; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory; the ability to remain competitive; the ability to innovate, develop and introduce new products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company’s dependence on key independent agents for a significant portion of its revenue; the effect of COVID-19, labor and hospital staffing shortages on the Company’s business, operating results and financial condition, especially when they affect key markets; the Company’s ability to implement successfully its future growth initiatives and risks associated therewith; the effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company’s financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; risks associated with the Company’s clinical trials; international risks; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (SEC) on March 8, 2023 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 anticipated to be filed with the SEC. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.
Investor Relations Contact
David Carey
Lazar FINN
Ph: 212-867-1762
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| XTANT MEDICAL HOLDINGS, INC. | ||||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||||
| (In thousands, except number of shares and par value) | ||||||||||
| As of September 30, 2023 | As of December 31, 2022 | |||||||||
| (Unaudited) | ||||||||||
| ASSETS | ||||||||||
| Current Assets: | ||||||||||
| Cash and cash equivalents | $ | 8,664 | $ | 20,298 | ||||||
| Restricted Cash | 85 | 209 | ||||||||
| Trade accounts receivable, net of allowance for credit losses and doubtful accounts of $820 and $515, respectively | 19,150 | 10,853 | ||||||||
| Inventories | 34,334 | 17,285 | ||||||||
| Prepaid and other current assets | 1,874 | 673 | ||||||||
| Total current assets | 64,107 | 49,318 | ||||||||
| Property and equipment, net | 9,097 | 5,785 | ||||||||
| Right-of -use asset, net | 1,594 | 1,380 | ||||||||
| Goodwill | 6,514 | 3,205 | ||||||||
| Intangible assets, net | 10,492 | 344 | ||||||||
| Other assets | 199 | 197 | ||||||||
| Total Assets | $ | 92,003 | $ | 60,229 | ||||||
| LIABILITIES & STOCKHOLDERS' EQUITY | ||||||||||
| Current Liabilities: | ||||||||||
| Accounts payable | $ | 5,358 | $ | 3,490 | ||||||
| Accrued liabilities | 8,934 | 5,496 | ||||||||
| Current portion of lease liability | 733 | 458 | ||||||||
| Current portion of finance lease obligations | 64 | 62 | ||||||||
| Line of credit | 3,999 | 3,379 | ||||||||
| Current portion of long-term debt | 2,833 | 2,333 | ||||||||
| Total current liabilities | 21,921 | 15,218 | ||||||||
| Long-term Liabilities: | ||||||||||
| Lease liability, less current portion | 916 | 972 | ||||||||
| Finance lease obligations, less current portion | 133 | 181 | ||||||||
| Long-term debt, plus premium and less issuance costs | 14,352 | 9,687 | ||||||||
| Total Liabilities | 37,322 | 26,058 | ||||||||
| Stockholders' Equity | ||||||||||
| Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding | - | - | ||||||||
| Common stock, $0.000001 par value; 300,000,000 shares authorized; 129,788,947 shares issued and outstanding as of September 30, 2023 and 108,874,803 shares issued and outstanding as of December 31, 2022 | - | - | ||||||||
| Additional paid-in capital | 293,534 | 277,841 | ||||||||
| Accumulated other comprehensive loss | (146 | ) | - | |||||||
| Accumulated deficit | (238,707 | ) | (243,670 | ) | ||||||
| Total Stockholders’ Equity | 54,681 | 34,171 | ||||||||
| Total Liabilities & Stockholders’ Equity | $ | 92,003 | $ | 60,229 | ||||||
| XTANT MEDICAL HOLDINGS, INC. | ||||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||||
| (Unaudited, in thousands, except number of shares and per share amounts) | ||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||||
| Total revenue | $ | 25,019 | $ | 14,462 | $ | 63,195 | $ | 42,699 | ||||||||||
| Cost of sales | 9,685 | 6,566 | 24,865 | 18,868 | ||||||||||||||
| Gross profit | 15,334 | 7,896 | 38,330 | 23,831 | ||||||||||||||
| Gross profit % | 61.3 | % | 54.6 | % | 60.7 | % | 55.8 | % | ||||||||||
| Operating expenses | ||||||||||||||||||
| General and administrative | 7,144 | 3,729 | 16,983 | 11,496 | ||||||||||||||
| Sales and marketing | 11,085 | 5,838 | 26,855 | 16,683 | ||||||||||||||
| Research and development | 490 | 229 | 844 | 683 | ||||||||||||||
| Total operating expenses | 18,719 | 9,796 | 44,682 | 28,862 | ||||||||||||||
| Loss from operations | (3,385 | ) | (1,900 | ) | (6,352 | ) | (5,031 | ) | ||||||||||
| Other Income (Expense) | ||||||||||||||||||
| Interest expense | (760 | ) | (440 | ) | (2,120 | ) | (1,197 | ) | ||||||||||
| Interest income | 48 | - | 133 | - | ||||||||||||||
| Bargain purchase gain | 11,028 | - | 11,028 | - | ||||||||||||||
| Total Other Expense | 10,316 | (440 | ) | 9,041 | (1,197 | ) | ||||||||||||
| Net Income (Loss) Before Provision for Income Taxes | 6,931 | (2,340 | ) | 2,689 | (6,228 | ) | ||||||||||||
| Provision for Income Taxes Current and Deferred | 2,300 | (13 | ) | 2,274 | (48 | ) | ||||||||||||
| Net Income (Loss) | $ | 9,231 | $ | (2,353 | ) | $ | 4,963 | $ | (6,276 | ) | ||||||||
| Net loss per share: | ||||||||||||||||||
| Basic | $ | 0.07 | $ | (0.03 | ) | $ | 0.04 | $ | (0.07 | ) | ||||||||
| Dilutive | $ | 0.07 | $ | (0.03 | ) | $ | 0.04 | $ | (0.07 | ) | ||||||||
| Shares used in the computation: | ||||||||||||||||||
| Basic | 128,140,238 | 93,278,610 | 115,380,792 | 89,236,832 | ||||||||||||||
| Dilutive | 138,663,274 | 93,278,610 | 123,832,401 | 89,236,832 | ||||||||||||||
| XTANT MEDICAL HOLDINGS, INC. | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| (Unaudited, in thousands) | ||||||||
| Nine Months Ended September 30, | ||||||||
| 2023 | 2022 | |||||||
| Operating activities: | ||||||||
| Net income (loss) | $ | 4,963 | $ | (6,276 | ) | |||
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 2,157 | 971 | ||||||
| Gain on disposal of fixed assets | (104 | ) | (91 | ) | ||||
| Non-cash interest | 266 | 175 | ||||||
| Non-cash rent | 5 | 2 | ||||||
| Stock-based compensation | 1,801 | 1,825 | ||||||
| Provision for expected credit losses | 316 | 277 | ||||||
| Provision for excess and obsolete inventory | 398 | 1,568 | ||||||
| Release of valuation allowance | (2,394 | ) | - | |||||
| Gain on bargain purchase | (11,028 | ) | - | |||||
| Changes in operating assets and liabilities, net of acquisition effects: | ||||||||
| Accounts receivable | (7,047 | ) | (2,962 | ) | ||||
| Inventories | (1,669 | ) | (616 | ) | ||||
| Prepaid and other assets | 69 | 239 | ||||||
| Accounts payable | 1,298 | 1,164 | ||||||
| Accrued liabilities | 2,369 | 671 | ||||||
| Net cash used in provided by operating activities | (8,600 | ) | (3,053 | ) | ||||
| Investing activities: | ||||||||
| Purchases of property and equipment | (1,093 | ) | (1,321 | ) | ||||
| Proceeds from sale of fixed assets | 70 | 184 | ||||||
| Acquisition of Surgalign SPV, Inc. | (17,000 | ) | - | |||||
| Acquisition of Surgalign Holdings, Inc.'s hardware and biologics business, net of cash acquired | (4,448 | ) | - | |||||
| Net cash used in investing activities | (22,471 | ) | (1,137 | ) | ||||
| Financing activities: | ||||||||
| Payments on financing leases | (46 | ) | (35 | ) | ||||
| Borrowings on line of credit | 55,345 | 36,680 | ||||||
| Repayments of line of credit | (54,724 | ) | (39,580 | ) | ||||
| Proceeds from private placement, net of cash issuance costs | 14,011 | 6,341 | ||||||
| Proceeds from issuance of long-term debt, net of issuance costs | 4,899 | - | ||||||
| Payments of taxes from withholding of common stock on vesting of restricted stock units | (119 | ) | - | |||||
| Net cash provided by financing activities | 19,366 | 3,406 | ||||||
| Effect of exchange rate changes on cash and cash equivalents and restricted cas | (53 | ) | - | |||||
| Net change in cash and cash equivalents and restricted cash | (11,758 | ) | (784 | ) | ||||
| Cash and cash equivalents and restricted cash at beginning of period | 20,507 | 18,387 | ||||||
| Cash and cash equivalents and restricted cash at end of period | $ | 8,749 | $ | 17,603 | ||||
| Reconciliation of cash and restricted cash reported in the condensed consolidated balance sheets | ||||||||
| Cash and cash equivelants | $ | 8,664 | $ | 18,175 | ||||
| Restricted cash | 85 | 439 | ||||||
| Total cash and restricted cash reported in the condensed consolidated balance sheets | $ | 8,749 | $ | 18,614 | ||||
| XTANT MEDICAL HOLDINGS, INC. | ||||||||||||||||||
| CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA | ||||||||||||||||||
| (Unaudited, in thousands) | ||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||||
| Net Income (Loss) | $ | 9,231 | $ | (2,353 | ) | $ | 4,963 | $ | (6,276 | ) | ||||||||
| Depreciation and amortization | 903 | 372 | 2,175 | 971 | ||||||||||||||
| Interest expense | 712 | 440 | 1,987 | 1,197 | ||||||||||||||
| Tax (benefit) expense | (2,300 | ) | 13 | (2,274 | ) | 48 | ||||||||||||
| Non-GAAP EBITDA | 8,546 | (1,528 | ) | 6,851 | (4,060 | ) | ||||||||||||
| Non-GAAP EBITDA/Total revenue | 34.2 | % | -10.6 | % | 10.8 | % | -9.5 | % | ||||||||||
| NON-GAAP ADJUSTED EBITDA CALCULATION | ||||||||||||||||||
| Non-cash compensation | 745 | 640 | 1,800 | 1,825 | ||||||||||||||
| Acquisition-related expenses | 1,023 | - | 1,326 | - | ||||||||||||||
| Acquisition-related fair value adjustments | 1,026 | - | 1,188 | - | ||||||||||||||
| Gain on bargain purchase | (11,028 | ) | - | (11,028 | ) | - | ||||||||||||
| Litigation settlement reserve | 140 | - | 140 | 550 | ||||||||||||||
| Non-GAAP Adjusted EBITDA | $ | 452 | $ | (888 | ) | $ | 277 | $ | (1,685 | ) | ||||||||
| Non-GAAP Adjusted EBITDA/Total revenue | 1.8 | % | -6.1 | % | 0.4 | % | -3.9 | % | ||||||||||
| Last Trade: | US$0.53 |
| Daily Change: | -0.0019 -0.35 |
| Daily Volume: | 50,624 |
| Market Cap: | US$74.090M |
September 23, 2024 September 18, 2024 August 08, 2024 August 08, 2024 July 25, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
